BSX
Boston Scientific Corporation NYSE$56.50
After hrs
$56.91
+0.11%
Mkt Cap $84.4B
52w Low $56.05
0.8% of range
52w High $109.50
50d MA $67.70
200d MA $90.46
P/E (TTM)
28.8x
EV/EBITDA
40.6x
P/B
3.4x
Debt/Equity
0.5x
ROE
11.9%
P/FCF
38.6x
RSI (14)
—
ATR (14)
—
Beta
0.78
50d MA
$67.70
200d MA
$90.46
Avg Volume
19.1M
About
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardiov…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 22, 2026 | AMC | 0.79 | 0.80 | +1.5% | 64.87 | +1.1% | +1.3% | -4.3% | -7.6% | -9.9% | -11.9% | — | — |
| Feb 4, 2026 | AMC | 0.78 | 0.80 | +2.4% | 75.50 | +2.5% | +2.8% | +1.0% | -1.8% | -1.7% | -2.7% | -5.5% | — |
| Oct 22, 2025 | AMC | 0.71 | 0.75 | +5.0% | 103.85 | +0.4% | -1.4% | -2.6% | -1.4% | -2.8% | -3.4% | -6.7% | — |
| Jul 23, 2025 | AMC | 0.72 | 0.75 | +3.4% | 107.76 | +0.5% | -1.4% | -1.5% | -1.8% | -1.2% | -0.9% | -1.5% | — |
| Apr 23, 2025 | AMC | 0.67 | 0.75 | +11.4% | 98.87 | +0.2% | +2.3% | +3.1% | +3.3% | +3.9% | +4.0% | +5.7% | — |
| Feb 5, 2025 | AMC | 0.66 | 0.70 | +6.5% | 104.97 | +0.7% | +0.0% | +0.3% | +1.2% | +1.0% | +0.8% | -5.6% | — |
| Oct 23, 2024 | AMC | 0.59 | 0.63 | +7.1% | 87.45 | +1.1% | -2.7% | -3.1% | -3.1% | -3.3% | -4.0% | +2.9% | — |
| Jul 24, 2024 | AMC | 0.58 | 0.62 | +6.3% | 77.76 | +0.6% | -4.5% | -3.7% | -2.8% | -4.8% | -5.0% | +1.8% | — |
| Apr 24, 2024 | AMC | 0.51 | 0.56 | +8.9% | 72.91 | +0.3% | +0.5% | +0.4% | -0.6% | -1.4% | -1.0% | +3.7% | — |
| Jan 31, 2024 | AMC | 0.51 | 0.55 | +7.8% | 63.26 | +1.9% | +2.5% | +1.8% | +1.9% | +2.4% | +3.1% | +6.1% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 23 | Wells Fargo | Maintains | Overweight → Overweight | — | $64.87 | $65.57 | +1.1% | +1.3% | -4.3% | -7.6% | -9.9% | -11.9% |
| Apr 23 | RBC Capital | Maintains | Outperform → Outperform | — | $64.87 | $65.57 | +1.1% | +1.3% | -4.3% | -7.6% | -9.9% | -11.9% |
| Apr 23 | Baird | Maintains | Outperform → Outperform | — | $64.87 | $65.57 | +1.1% | +1.3% | -4.3% | -7.6% | -9.9% | -11.9% |
| Apr 23 | Truist | Maintains | Buy → Buy | — | $64.87 | $65.57 | +1.1% | +1.3% | -4.3% | -7.6% | -9.9% | -11.9% |
| Apr 23 | Barclays | Maintains | Overweight → Overweight | — | $64.87 | $65.57 | +1.1% | +1.3% | -4.3% | -7.6% | -9.9% | -11.9% |
| Apr 23 | Needham | Maintains | Buy → Buy | — | $64.87 | $65.57 | +1.1% | +1.3% | -4.3% | -7.6% | -9.9% | -11.9% |
| Apr 23 | Goldman Sachs | Maintains | Buy → Buy | — | $64.87 | $65.57 | +1.1% | +1.3% | -4.3% | -7.6% | -9.9% | -11.9% |
| Apr 23 | Evercore ISI | Maintains | Outperform → Outperform | — | $64.87 | $65.57 | +1.1% | +1.3% | -4.3% | -7.6% | -9.9% | -11.9% |
| Apr 23 | Canaccord Genuity | Maintains | Buy → Buy | — | $64.87 | $65.57 | +1.1% | +1.3% | -4.3% | -7.6% | -9.9% | -11.9% |
| Apr 22 | Jefferies | Maintains | Buy → Buy | — | $59.52 | $62.51 | +5.0% | +9.0% | +10.4% | +4.3% | +0.7% | -1.8% |
Recent Filings
8-K
Boston Scientific Corp. -- 8-K Filing
Boston Scientific delivered strong Q1 2026 results with 11.6% reported sales growth to $5.2 billion and doubled net income to $1.341 billion, signaling robust operational momentum for shareholders.
Apr 22
8-K · 5.02
!!! Very High
Envoy Medical, Inc. -- 8-K 5.02: Executive Change
Charles S. McKhann joined Envoy Medical's board as a Class I director, potentially bringing new expertise and perspective to the company's governance and strategic direction.
Apr 21
S-4
!!! Very High
Unknown — Merger Registration
BSX shareholders are receiving $374 cash per share in a merger, providing immediate liquidity but eliminating future upside potential from the combined entity.
Mar 30
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Boston Scientific's EKOS system achieved superior clinical outcomes in a major PE treatment trial, potentially expanding its addressable market and supporting premium pricing for this interventional device.
Mar 30
8-K
Unknown — 8-K Filing
ELUT's NXT-41 FDA submission positions the company for potential 2026-2027 clearances, but limited cash ($44.4M) raises dilution concerns for investors awaiting clinical validation and regulatory milestones.
Mar 11
S-4
!!! Very High
Boston Scientific Corp. -- Merger Registration
Boston Scientific completed a merger with approximately $374 million in cash reserves, indicating the company retained substantial liquidity for post-combination operations and strategic investments.
Feb 27
8-K · 1.01
! Medium
Boston Scientific Corp. -- 8-K 1.01: Financing / Debt Agreement
Boston Scientific secured a $3 billion revolving credit facility with Wells Fargo, providing flexible liquidity for operational and strategic needs.
Feb 26
8-K · 5.02
!!! Very High
Boston Scientific Corp. -- 8-K 5.02: Executive Change
Boston Scientific appointed Catherine R. Smith and Christophe P. Weber as directors effective February 18, 2026, strengthening board composition with new independent oversight.
Feb 23
8-K · 5.02
!!! Very High
Boston Scientific Corp. -- 8-K 5.02: Executive Change
Yoshiaki Fujimori's decision not to seek re-election at Boston Scientific reduces board continuity, potentially signaling leadership transition or strategic shifts within the company's governance structure.
Feb 5
8-K
Boston Scientific Corp. -- 8-K Filing
Boston Scientific reported fourth-quarter 2025 net sales of $5.286 billion, achieving 15.9% reported growth driven by strong operational and organic expansion across its business.
Feb 4
Data updated apr 24, 2026 10:59pm
· Source: massive.com